Isogenica Ltd

Isogenica's advanced synthetic antibody libraries and display technologies enable and accelerate our partners' therapeutic antibody discovery programmes. Isogenica was originally launched to develop and operate its proprietary cell-free, DNA-based display technology, CIS display, as a platform for the discovery of polypeptide biologics.

Following the acquisition and development of further technologies, including the Colibra™ DNA library building platform, we now offer opportunities for discovery partnerships with access to our skills and tools, including next-generation, best-in-class antibody libraries such as our camelid VHH (llamdA™), Fab fragment and human scFv (Xab™) libraries.

These libraries are available for license and screening partnerships which, together with our expertise in the screening of displayed peptide and scaffold libraries, can facilitate your biologics discovery needs.